Hormone in Biological Technology

Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity

... comprising pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, in overweight and obese patients. This ... acetate is a synthetic analog of the natural hormone amylin, a neurohormone secreted by the pancreas ...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

... Prostate Cancer Drugs & Companies II-2 hormone Therapies to Dominate Global Prostate Cancer ... Approval II-12 Ongoing Clinical Trials in hormone Refractory Prostate Cancer II-12 Challenges ... II-32 Hormonal Therapy II-32 Medical hormone Therapy II-32 LHRH Analogs II-33 Dose of ...

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

... efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days. The ... data demonstrated that endogenous luteinizing hormone (LH) levels do not affect ongoing pregnancy rates ... with a standardized rFSH / gonadotropin-releasing hormone (GnRH) antagonist protocol.(3) An analysis ...

Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August

... and treatment of bone loss in patients undergoing hormone ablation for either prostate or breast cancer. ... treatment for the men and women receiving hormone ablation therapy for prostate or breast cancer ... prevention of bone loss in patients undergoing hormone ablation for prostate or breast cancer. ...

AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130

... ("Ardana"), the worldwide rights to the growth hormone secretagogue ("GHS") / ghrelin agonist, AEZS-130, ... the use of AEZS-130 for the diagnostic of growth hormone secretion deficiency. Ardana had developed ... for use as an oral diagnostic test of growth hormone secretion deficiency. In addition to the ...

New Analysis Finds Bioidentical Hormones Safer Than Standard Hormone Replacement Therapy

... counterparts. Conducted by a leading expert in hormone replacement, Kent Holtorf, M.D., medical director ... studies. It demonstrated that bioidentical hormone replacement therapy is both more effective and ... women suffering with symptoms of menopause than hormone replacement therapy with synthetic hormones. ...

FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab

... prevention of bone loss in patients undergoing hormone ablation therapy for either prostate or breast ... PMO and bone loss in patients undergoing hormone ablation for prostate and breast cancer, as well ... cancer and breast cancer patients to receive hormone ablation therapies that can lead to a decrease in ...

Secretropin(R) - Effective, Preferable, Affordable as an Alternative to Injectable Growth Hormone - Gains Momentum

... clinically proven natural stimulator of growth hormone production, is gaining the medical community's ... been shown to increase the production of growth hormone by 50 - 200% while being delivered as an oral ... agents responsible for the increase in growth hormone production. Prior to Secretropin(R), this ...

Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone

... its longer-acting version of human growth hormone (hGH). The new grant follows the company's ... NIS (about $2.6 million). Human growth hormone is a natural protein produced by the pituitary ... 95% of children diagnosed with a growth hormone deficiency receive treatment. The current annual ...

Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product

... of the company's proprietary long-acting growth hormone product, which is being developed as a potential treatment for growth hormone deficiency, short stature in children and ... support from NIAID for our long-acting growth hormone program. Funding from a Phase I SBIR grant from ...

Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated

... ARX201, the company's long-acting human growth hormone (hGH) analogue developed in collaboration with ... and tolerability profile in adults with Growth hormone deficiency. The results of this trial support ... ARX201 is a long-acting recombinant human growth hormone drug candidate currently developed by Ambrx and ...

OncoGenex Reports Third Quarter Financial Results

... trial of OGX-011 in patients with hormone refractory prostate cancer via the Special ... its lead product candidate targeting hormone refractory prostate cancer, via the SPA process. ... approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC). In ...

Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue

... of ARX201, the company's long-acting human growth hormone (hGH) analogue developed in collaboration with ... ARX201 is a long-acting recombinant human growth hormone drug candidate currently developed by Ambrx and ... performance over existing growth hormone products, including the potential for less ...

FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children

... in the normal range of their peers. "Growth hormone therapy is the only treatment currently available ... and maternal factors. The natural growth hormone level of children born SGA varies from normal to ... due to insensitivity to the body's own growth hormone and/or other growth factors. Growth ...

AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

... cetrorelix, a Luteinizing Hormone Releasing hormone (LHRH) antagonist. This second efficacy ... is part of AEterna Zentaris' Luteinizing hormone Releasing hormone (LHRH) antagonist therapeutic approach. This ...

Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO

... transdermal patch formulation of parathyroid hormone (PTH) for the treatment of established ... transdermal patch formulation of parathyroid hormone (PTH) for the treatment of established ... lead clinical program is evaluating a parathyroid hormone (hPTH 1-34) transdermal patch for the treatment ...

Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today

... chemotherapy, radiation therapy, and hormone ablation therapy. Recently announced preliminary ... second-line chemotherapy in patients with hormone refractory prostate cancer has shown that ... in response to many cancer treatments including hormone ablation therapy, chemotherapy and radiation ...

Sonus Pharmaceuticals and OncoGenex Technologies to Merge

... Products in Clinic - - Lead Candidate Targets hormone Refractory Prostate and Non-Small Cell ... chemotherapy, radiation therapy, and hormone ablation therapy. Preliminary data in a Phase 2 ... second-line chemotherapy in patients with hormone refractory prostate cancer has shown that ...

Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty

... that SUPPRELIN LA demonstrated continued profound hormone suppression with no escapes (breakthrough of ... LA maintains remarkable suppression of peak hormone and sex steroid levels for two years in children ... annually. Primary outcome was peak luteinizing hormone (LH), which helps regulate the menstrual ...

JCI table of contents: April 22, 2008

... REPRODUCTIVE BIOLOGY: How is a regulator of sex hormone production regulated itself? The production ... other hormones, which are known as luteinizing hormone (LH) and follicle stimulating hormone (FSH). Disturbances in the levels of either LH or ...

NPS Pharmaceuticals Reports 2007 Financial Results

... orphan drug status for NPSP558 (parathyroid hormone 1-84 [rDNA origin injection]) as a potential ... with Nycomed for Preotact(R) (parathyroid hormone [rDNA origin] injection), (ii) increased royalty ... short bowel syndrome and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is in Phase 2 ...

MannKind Corporation Response to Recent Market Events

... associated with the ability to deliver a peptide hormone in ways that mimic normal hormone physiology. The ... Insulin and MKC253. A third peptide hormone for the treatment of obesity is in preclinical ... of Technosphere(R) Insulin and its other peptide hormone drug candidates on attractive terms for ...

WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy

... hormone Therapy Remains an Important Option for Women ... new insight into the appropriate use of hormone therapy when it is prescribed to symptomatic, ... a division of Wyeth (NYSE: WYE ), believes that hormone therapy, when used appropriately, remains a good ...

NPS Pharmaceuticals Announces Senior Management Changes

... with short bowel syndrome and parathyroid hormone 1-84 [rDNA origin] injection is in Phase 2 clinical development as a hormone therapy for hypoparathyroidism (parathyroid hormone 1-84 [rDNA origin] injection). NPS has also ...

Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation

... the potentially debilitating symptoms of thyroid hormone withdrawal. Genzyme received additional European ... enhanced. Patients currently stop taking thyroid hormone supplements to elevate TSH levels. Doing ... injection, allowing patients to continue taking hormone supplements and avoid the symptoms associated ...

MultiVu Video Feed: Easypod(R), Award-Winning Electronic Device

... FOR GROWTH hormone THERAPY, NOW AVAILABLE IN THE U.S. -- Device ... an advancement in the use of technology in growth hormone delivery devices. The first of its kind device ... NEWS: New Injection Device Available for Growth hormone Therapy FORMAT: News Package with Extra ...

Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device

... first of its kind automated device in the growth hormone therapeutic area. easypod(R) was developed for ... the company's treatment for growth hormone deficiency. A 2007 Gold Medal recipient of the ... "As a physician who treats children with growth hormone deficiency, I am encouraged by the new technology ...

PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism

... drug designation to PREOS(R) (parathyroid hormone [rDNA origin] for injection) for the treatment of ... a rare deficiency of parathyroid hormone for which there is no FDA-approved therapy. ... therapies, the absence of endogenous parathyroid hormone compromises the body's ability to properly absorb ...

PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group

... significant milestones in the development of our long-acting human growth hormone candidate that has the potential to significantly decrease the frequency ... development, as well as GLP-1. The company's long-acting human growth hormone drug candidate, which is expected to enter clinical trials in the coming ...

Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens

... structural classes, adds to the Company portfolio of topically acting hormone receptor modulators. HYG-440 will undergo preclinical development for the ... corporate partnerships interested in safe and efficacious topical hormone modulators in the therapeutic areas of dermatology and women's ...

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

... proceeding towards clinical development of an oral form of the peptide hormone drug leuprolide using the LPM(TM) technology. Leuprolide is a synthetic peptide agonist of gonadotropin releasing hormone (GnRh) that is used in treatment of endometriosis in women and prostate ...

AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction

... the treatment of alcohol dependence that involves ghrelin. Ghrelin is a hormone produced by the stomach and acting in the brain. Compelling evidence ... Zentaris' Ghrelin Antagonist Program Ghrelin is a natural peptide hormone produced by the stomach that increases appetite and induces accumulation ...

PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth Hormone and Longer-Acting Erythropoietin

... two new patents for the company's long-acting CTP-enhanced human growth hormone (hGH-CTP) and human erythropoietin (EPO-CTP). The patents cover the ... the body. "These two new patents covering CTP-enhanced human growth hormone and erythropoietin represent another significant layer of protection ...

Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer

... 3 trial of Stimuvax(R) (BLP25 liposome vaccine, L-BLP25) in patients with hormone receptor-positive, locally advanced, recurrent or metastatic breast ... study prove positive, this could make a difference for patients with hormone receptor positive metastatic breast cancer." "The initiation of the ...

Novo Nordisk Convenes Policy and Clinical Experts at Diabetes Media Summit

... has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom ...

AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting

... F. Brands, J. Engel, J. Pinski, investigates the expression of Luteinizing hormone Releasing hormone (LHRH) receptors following prolonged exposure to LHRH agonists. "Results ...

AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting

... indications, the new results show continued expression of Luteinizing hormone Releasing hormone (LHRH) receptors in prostate cancer specimens after prolonged use of LHRH ...

AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia

... (BPH) for the U.S. market. Cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, is currently in a Phase 3 program in BPH, a ... Cetrorelix is part of AEterna Zentaris' luteinizing hormone-releasing hormone (LHRH) antagonist therapeutic approach. This peptide-based active ...

Bert W. O'Malley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovo's Scientific Advisory Board

... research. Dr. O'Malley's landmark discoveries revealed the mechanism of hormone action and the critical importance of a previously undiscovered ... pregnancy maintenance, and prenatal embryonic development, and for the hormone mediated embryonic and pubertal growth of breast, uterine, ovarian, ...

The Holtorf Medical Group and Yan Center for Corrective & Cosmetic Surgery Tap 5W Public Relations

... M.D. is the Medical Director of the Holtorf Medical Group, Inc. Center for hormone Imbalance, Hypothyroidism and Fatigue. With centers located in Los Angeles ... Francisco, Dr. Holtorf and his staff are experts in natural bioidentical hormone replacement and optimization for women and men, as well as chronic fatigue ...